Summary:
- The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has announced a pause in the Pathways clinical trial, which was investigating the use of puberty suppression in children and young people with gender incongruence.
- This pause is to allow for a review of the trial's design and procedures to ensure they are appropriate and in line with the latest evidence and guidelines.
- The Department of Health and Social Care (DHSC) has stated that this pause does not reflect any safety concerns about the treatment, but rather a need to ensure the trial is conducted to the highest standards.